SLC5A2 and chronic obstructive pulmonary disease: A meta-analysis of randomised trials of sodium–glucose transporter 2 (SGLT2) inhibitors showed a trend towards a reduced risk of COPD with these drugs (RR, 0.79, 95% CI: 0.61–1.02) [89].